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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To compare the efficacy and safety of pegylated G-CSF versus non-pegylated G-CSF for patients after HSCT.
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B A C K G R O U N D
Description of the condition
Since the first bone marrow transplant in 1958 by Georges Mathé,
a French oncologist, and the use of bone-marrow-derived stem
cells pioneered by a team led by E. Donnall Thomas at the Fred
Hutchinson Cancer Research Center (Seattle, WA, US) from the
1950s through the 1970s, there have been many advances in this
field. One of the major breakthroughs was the discovery of gran-
ulocyte colony stimulating factor (G-CSF).
G-CSF is a glycosylated hormone produced by the human body
for the function of granulocyte production stimulation. The pro-
duction of this hormone is controlled by the gene located on chro-
mosome 17q21-22. The first successful purification of this hor-
mone was in 1985 (Nomura 1986; Welte 1985) following the suc-
cessful purification of the G-CSF from rat in 1983 (Nicola 1983).
G-CSF was initially used to treat and shorten chemotherapy-in-
duced neutropenia. However, it was later found to be effective in
increasing the number of circulating hematopoietic stem cells and
enabling the adequate number of stem cells to be collected from
the peripheral blood using an apheresis machine. Hence peripheral
blood stem cells have emerged as another source of hematopoietic
stem cells with less pain and less postdonation restriction compared
with conventional bone marrow transplantation (Siddiq 2009).
The term ”bone marrow transplantation” was then changed to
’hematopoietic stem cell transplantation’ (HSCT).
Shortly after HSCT, morbidity and mortality is mainly dependent
on how soon the engraftment occurs. The sooner the engraftment
takes place, the lower the risks of morbidity and mortality due to
neutropenic sepsis. This situation is similar to postchemotherapy
neutropenia. G-CSF was found to have shortened the engraft-
ment time and thus reduced hospitalization period, morbidity and
mortality post HSCT (Dekker 2006; Schmitz 1995; Sung 2007).
Hence, G-CSF is indicated in patients following HSCT to pro-
mote engraftment, which is another important use for G-CSF in
addition to peripheral blood stem cell mobilization. However, the
initial form of recombinant human G-CSF has a very short half-
life and needs to be administered daily or even twice daily in order
to achieve a sustained effective blood concentration. Therefore, a
new form of recombinant human G-CSF, pegylated G-CSF, with
a longer half-life and higher potency, has been developed to over-
come this problem.
Description of the intervention
Currently there are only a few non-pegylated recombinant human
G-CSF available commercially (i.e. filgrastim, lenograstim and
nartograstim). All of the G-CSFs are administered subcutaneously
and have a short half-life (with the exception of nartograstim).
Filgrastim (Neupogen®, Amgen Inc.) is a non-glycosylated G-
CSF with one additional amino acid, methionine, at its N-termi-
nal compared with human G-CSF. It is derived from Escherichia
coli (E. coli) and was the first recombinant human G-CSF ap-
proved for clinical use in the US (Molineux 2004). The half-life
of filgrastim is about three and a half hours. It is eliminated via a
static phase that correlates with renal excretion, which is the pre-
dominant route, and a phase that varies with the white cell count
because of neutrophil receptor-mediated endocytosis and degra-
dation.
Lenograstim (Granocyte®, Chugai Pharmaceutical Co. Ltd.) is an
authentic glycosylated recombinant human G-CSF that is derived
from Chinese hamster ovary cells. Its half-life at steady state is
about three to four hours if given subcutaneously but only one to
two hours if given intravenously. As glycosylated G-CSF is more
stable than non-glycosylated G-CSF in terms of temperature, pH
and degradation by proteases in vitro, lenograstim can be trans-
ported and stored at room temperature. Glycosylated G-CSF is
also more potent than non-glycosylated G-CSF on a weight for
weight basis. Despite the physical chemistry and bioactivity ad-
vantages, there are no prospective randomized control trials to
show the superiority of lenograstim over filgrastim after HSCT.
However, there are two retrospective studies comparing lenogras-
tim versus filgrastim after HSCT (Huttmann 2005; Kim 2003).
One of the studies showed no difference in terms of effectiveness
between these two G-CSFs (Huttmann 2005) but the other fa-
vored filgrastim in reducing the duration of neutropenia, throm-
bocytopenia and days of G-CSF administration, leading to ear-
lier hospital discharge (Kim 2003). The differences observed in
this study could be attributed to gender differences as lenograstim
has been reported to be more effective in mobilizing stem cells in
males than in females (Fischer 2005; Ings 2006).
Nartograstim (Neu-Up®, Kyowa Hakko Kirin Co. Ltd.) is a non-
glycosylated mutated recombinant human G-CSF derived from
E. coli. It has two to four times higher specific activity, and more
physicochemical, biologic, and pharmacokinetic stability, than fil-
grastim (Okabe 1990). Its half-life is about nine hours and one
hour via subcutaneously and intravenously injection, respectively.
Currently pegfilgrastim and pegnartograstim are the only two pe-
gylated forms of recombinant human G-CSF.
Pegfilgrastim (Neulasta®, Amgen Inc. and Peglasta®, Kyowa
Hakko Kirin Co. Ltd.) is the pegylated form of filgrastim. It is a
product of covalent conjugation between lgrastim and a mono-
methoxypolyethylene glycol (PEG) molecule at the N-terminal
of the methionyl residual. Pegfilgrastim has limited renal clear-
ance owing to the increased molecular weight of the PEG group.
Hence, neutrophil-regulated kinetics become the primary route of
clearance (> 99%) for pegfilgrastim. The half-life of pegfilgrastim
ranges from 15 to 80 hours after subcutaneous injection for a pa-
tient with a normal neutrophil count. For a patient who is neu-
tropenic following chemotherapy, the drug concentration remains
in the therapeutic range initially and starts to fall as the neutrophil
count recovers (Fenk 2006; Mey 2007; Zamboni 2003).
Pegnartograstim (synonym: Ro-25-8315, Kyowa Hakko Kirin Co.
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